These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
572 related items for PubMed ID: 1709446
21. Overview of pharmacological treatment of Kawasaki disease. Onouchi Z, Kawasaki T. Drugs; 1999 Nov; 58(5):813-22. PubMed ID: 10595862 [Abstract] [Full Text] [Related]
22. Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose. Terai M, Shulman ST. J Pediatr; 1997 Dec; 131(6):888-93. PubMed ID: 9427895 [Abstract] [Full Text] [Related]
23. Left ventricular contractility and function in Kawasaki syndrome. Effect of intravenous gamma-globulin. Newburger JW, Sanders SP, Burns JC, Parness IA, Beiser AS, Colan SD. Circulation; 1989 Jun; 79(6):1237-46. PubMed ID: 2720925 [Abstract] [Full Text] [Related]
24. [Evaluation of unresponsiveness to standard high-dose gamma globulin therapy in Kawasaki disease]. Tavli V, Yilmazer MM, Güven B, Meşe T, Oner T, Demirpençe S. Turk Kardiyol Dern Ars; 2010 Jan; 38(1):20-4. PubMed ID: 20215838 [Abstract] [Full Text] [Related]
25. Lack of effect of gamma-globulin infusion on circulating immune complexes in patients with Kawasaki syndrome. Mason W, Jordan S, Sakai R, Takahashi M. Pediatr Infect Dis J; 1988 Feb; 7(2):94-9. PubMed ID: 2449651 [Abstract] [Full Text] [Related]
26. Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease. Jibiki T, Terai M, Kurosaki T, Nakajima H, Suzuki K, Inomata H, Terashima I, Honda T, Yasukawa K, Hamada H, Kohno Y. Eur J Pediatr; 2004 Apr; 163(4-5):229-33. PubMed ID: 14963702 [Abstract] [Full Text] [Related]
27. Pentoxifylline and intravenous gamma globulin combination therapy for acute Kawasaki disease. Furukawa S, Matsubara T, Umezawa Y, Motohashi T, Ino T, Yabuta K. Eur J Pediatr; 1994 Sep; 153(9):663-7. PubMed ID: 7957426 [Abstract] [Full Text] [Related]
29. Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease. Han RK, Silverman ED, Newman A, McCrindle BW. Arch Pediatr Adolesc Med; 2000 Jul 06; 154(7):694-9. PubMed ID: 10891021 [Abstract] [Full Text] [Related]
30. [How does the time of diagnosis affect the course of disease in children with kawasaki syndrome? A retrospective analysis at one center]. Raith W, Gamillscheg A, Heinzl B, Nagel BH, Koestenberger M, Beitzke A. Klin Padiatr; 2009 Jul 06; 221(2):83-8. PubMed ID: 19263328 [Abstract] [Full Text] [Related]
32. Prediction of responsiveness or non-responsiveness to treatment of acute Kawasaki disease using 1 gram per kilogram of immunoglobulin--an effective and cost-saving schedule of therapy. Ichihashi K, Shiraishi H, Momoi M. Cardiol Young; 2009 Jun 06; 19(3):224-7. PubMed ID: 19272202 [Abstract] [Full Text] [Related]
33. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study]. Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX. Zhonghua Er Ke Za Zhi; 2006 Dec 06; 44(12):891-5. PubMed ID: 17254453 [Abstract] [Full Text] [Related]
34. Intravenous gammaglobulin and reduction of coronary artery abnormalities in children with Kawasaki Disease. Nishihara S, Ishibashi K, Iribe K, Matsuda I. Lancet; 1988 Oct 22; 2(8617):973. PubMed ID: 2459575 [No Abstract] [Full Text] [Related]
35. Coronary risk factors in acute Kawasaki disease: correlation of serum immunoglobulin levels with coronary complications. Sawaji Y, Haneda N, Yamaguchi S, Kajino Y, Kishida K, Seto S, Konishi N, Waki K, Baba K, Arisawa K, Kamiya T, Mori C. Acta Paediatr Jpn; 1998 Jun 22; 40(3):218-25. PubMed ID: 9695293 [Abstract] [Full Text] [Related]
36. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, Kato T, Hara T, Hamaoka K, Ogawa S, Miura M, Nomura Y, Fuse S, Ichida F, Seki M, Fukazawa R, Ogawa C, Furuno K, Tokunaga H, Takatsuki S, Hara S, Morikawa A, RAISE study group investigators. Lancet; 2012 Apr 28; 379(9826):1613-20. PubMed ID: 22405251 [Abstract] [Full Text] [Related]
37. Coronary risk factors in Kawasaki disease treated with additional gammaglobulin. Miura M, Ohki H, Tsuchihashi T, Yamagishi H, Katada Y, Yamada K, Yamashita Y, Sugaya A, Komiyama O, Shiro H. Arch Dis Child; 2004 Aug 28; 89(8):776-80. PubMed ID: 15269082 [Abstract] [Full Text] [Related]
38. Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children. Okada Y, Shinohara M, Kobayashi T, Inoue Y, Tomomasa T, Kobayashi T, Morikawa A, Gunma Kawasaki Disease Study Group. J Pediatr; 2003 Sep 28; 143(3):363-7. PubMed ID: 14517521 [Abstract] [Full Text] [Related]
39. Predictors of coronary artery lesions after intravenous gamma-globulin treatment in Kawasaki disease. Mori M, Imagawa T, Yasui K, Kanaya A, Yokota S. J Pediatr; 2000 Aug 28; 137(2):177-80. PubMed ID: 10931408 [Abstract] [Full Text] [Related]
40. Prediction of non-responsiveness to standard high-dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Sano T, Kurotobi S, Matsuzaki K, Yamamoto T, Maki I, Miki K, Kogaki S, Hara J. Eur J Pediatr; 2007 Feb 28; 166(2):131-7. PubMed ID: 16896641 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]